Ortho Regenerative Technologies Inc (CSE:ORTH) said it has fully activated half of the 10 clinical trial sites involved in its upcoming Phase 1/2 rotator cuff tear repair trial evaluating the company’s novel soft tissue repair regenerative technology.
Sites involved in the study are the Rothman Institute in Pennsylvania, the OrthoIndy Research Foundation in Indiana, University Orthopedics, in Pennsylvania, Tucson Orthopedics in Arizona, and the Holy Cross Orthopedic Institute in Florida, with site activation imminent at the OrthoVirginia Institute in Virginia.
The remaining four sites will be activated over the coming months, the company said.
READ: Ortho Regenerative Technologies awarded $500,000 grant to advance the development of its ORTHO-M platform for meniscus repair
Ortho Regenerative CEO Philippe Deschamps said budget negotiations had been completed for all of the centers but one and the majority of the clinical trial agreements had been executed, with site initiation visits either completed or soon to be completed.
He added that the company was very pleased with its choice of clinical trial sites.
“They were specifically chosen for the volume of patients they treat, the outstanding qualifications of their clinical investigators and their reputation for research excellence,” he said. “We look forward to start reporting soon on patient enrolment status.”
Ortho Regenerative said it intends to report regularly on key clinical milestones going forward, such as first patient recruitment, the end of the Phase 1 safety portion of the program after five patients have been treated, and general patient recruitment status at the end of each quarter.
Based in Montreal, Ortho Regenerative Technologies is an emerging orthobiotics company dedicated to the development of novel therapeutic soft tissue repair technologies to dramatically improve the success rate of orthopedic and sports medicine surgeries.
Contact the author Emily Jarvie at emily.jarvie@proactiveinvestors.com
Follow her on Twitter @emilyjjarvie